The Addition of Ofatumumab to the Conditioning Regimen Does Not Improve the Outcome of Patients with High-risk CLL Undergoing Reduced Intensity Allogeneic Haematopoietic Cell Transplantation: a Pilot Trial from the GETH and GELLC (CLL4 Trial)

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2016 May 24

PMID 27214073

Citations 2

Authors

P Montesinos

M Cabrero

D Valcarcel

M Rovira

J A Garcia-Marco

J Loscertales

C Moreno

R Duarte

M J Terol

N Villamor

P Abrisqueta

D Caballero

J Sanz

J Delgado

Affiliations

Soon will be listed here.

Citing Articles

The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review.

Puckrin R, Shafey M, Storek J Front Oncol. 2023; 12:1105779.

PMID: 36741737 PMC: 9889653. DOI: 10.3389/fonc.2022.1105779.

Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies.

Pflug N, Chakupurakal G, Fink A, Robrecht S, Herling M, Cramer P Hemasphere. 2021; 5(12):e664.

PMID: 34881358 PMC: 8647889. DOI: 10.1097/HS9.0000000000000664.

References

Rawstron A, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H . Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2012; 27(1):142-9. DOI: 10.1038/leu.2012.216. View

Ram R, Storb R . Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leuk Lymphoma. 2013; 54(8):1591-601. PMC: 3700680. DOI: 10.3109/10428194.2012.762978. View

Hahn M, Bottcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P . Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse. Bone Marrow Transplant. 2015; 50(10):1279-85. DOI: 10.1038/bmt.2015.150. View

Brown J, Kim H, Armand P, Cutler C, Fisher D, Ho V . Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2012; 27(2):362-9. PMC: 3519975. DOI: 10.1038/leu.2012.228. View

Pawluczkowycz A, Beurskens F, Beum P, Lindorfer M, van de Winkel J, Parren P . Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009; 183(1):749-58. DOI: 10.4049/jimmunol.0900632. View

Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-9. PMC: 1895304. DOI: 10.1182/blood-2005-05-2004. View

Wierda W, Kipps T, Mayer J, Stilgenbauer S, Williams C, Hellmann A . Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010; 28(10):1749-55. PMC: 4979101. DOI: 10.1200/JCO.2009.25.3187. View

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K . Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014; 123(21):3247-54. DOI: 10.1182/blood-2014-01-546150. View

Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J . Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2006; 21(1):12-7. DOI: 10.1038/sj.leu.2404441. View

10.

Michallet M, Socie G, Mohty M, Sobh M, Bay J, Morisset S . Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. Exp Hematol. 2012; 41(2):127-33. DOI: 10.1016/j.exphem.2012.10.008. View

11.

van Gelder M, van Oers M, Alemayehu W, Abrahamse-Testroote M, Cornelissen J, Chamuleau M . Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. Bone Marrow Transplant. 2016; 51(6):799-806. DOI: 10.1038/bmt.2016.9. View

12.

Sobecks R, Leis J, Gale R, Ahn K, Zhu X, Sabloff M . Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant. 2014; 20(9):1390-8. PMC: 4174349. DOI: 10.1016/j.bbmt.2014.05.020. View

13.

Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J . Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. Blood. 2014; 124(26):3841-9. PMC: 4276025. DOI: 10.1182/blood-2014-07-586826. View

14.

Khouri I, Bassett R, Poindexter N, OBrien S, Bueso-Ramos C, Hsu Y . Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011; 117(20):4679-88. PMC: 4371600. DOI: 10.1002/cncr.26091. View

15.

Nabhan C, Raca G, Wang Y . Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era. JAMA Oncol. 2015; 1(7):965-74. DOI: 10.1001/jamaoncol.2015.0779. View